دورية أكاديمية
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study.
| العنوان: | Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study. |
|---|---|
| المؤلفون: | Tout, Mira, Casasnovas, Olivier, Meignan, Michel, Lamy, Thierry, Morschhauser, Franck, Salles, Gilles, Gyan, Emmanuel, Haioun, Corinne, Mercier, Mélanie, Feugier, Pierre, Boussetta, Sami, Paintaud, Gilles, Ternant, David, Cartron, Guillaume |
| المساهمون: | Génétique, immunothérapie, chimie et cancer (GICC), UMR 7292 CNRS 2012-2017 (GICC UMR 7292 CNRS), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Lipides - Nutrition - Cancer Dijon - U1231 (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Microenvironnement et cancer (MiCa), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou Rennes, Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire Lille (CHRU Lille), Service d'hématologie, Hôpital Claude Huriez Lille, CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire Lille (CHRU Lille), Service d’Hématologie Centre Hospitalier Lyon Sud - HCL, Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Clinical Investigation Center - INSERM 1415, Service d'hématologie clinique, Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Unité des hémopathies lymphoïdes CHU Henri Mondor, CHU Henri Mondor Créteil, Service d'hématologie Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service d'Hématologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hospices Civils de Lyon (HCL), The European Lymphoma Institute, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Département d'hématologie biologique Montpellier, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Dynamique des interactions membranaires normales et pathologiques (DIMNP), Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS) |
| المصدر: | ISSN: 0006-4971. |
| بيانات النشر: | HAL CCSD American Society of Hematology |
| سنة النشر: | 2017 |
| المجموعة: | Archive Ouverte de l'Université Rennes (HAL) |
| مصطلحات موضوعية: | [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology |
| الوصف: | IF 13.164 ; International audience ; High variability in patient outcome after rituximab-based treatment is partly explained by rituximab concentrations, and pharmacokinetic (PK) variability could be influenced by tumor burden. We aimed at quantifying the influence of baseline total metabolic tumor volume (TMTV0) on rituximab PK and of TMTV0 and rituximab exposure on outcome in patients with diffuse large B-cell lymphoma (DLBCL). TMTV0 was measured by (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography in 108 previously untreated DLBCL patients who received four 375 mg/m(2) rituximab infusions every 2 weeks in combination with chemotherapy in 2 prospective trials. A 2-compartment population model allowed describing rituximab PK and calculating rituximab exposure (area under the concentration-time curve; AUC). The association of TMTV0 and AUC with metabolic response after 4 cycles, as well as progression-free survival (PFS) and overall survival (OS), was assessed using logistic regression and Cox models, respectively. Cutoff values for patient outcome were determined using receiver operating characteristic curve analysis. Exposure to rituximab decreased as TMTV0 increased (R(2) = 0.41, P < .0001). A high AUC in cycle 1 (≥9400 mg × h per liter) was associated with better response (odds ratio, 5.56; P = .0006) and longer PFS (hazard ratio [HR], 0.38; P = .011) and OS (HR, 0.17; P = .001). A nomogram for rituximab dose needed to obtain optimal AUC according to TMTV0 was constructed, and the 375 mg/m(2) classical dose would be suitable for patients with TMTV0 <281 cm(3) In summary, rituximab exposure is influenced by TMTV0 and correlates with response and outcome of DLBCL patients. Dose individualization according to TMTV0 should be evaluated in prospective studies. These studies were registered at www.clinicaltrials.gov as #NCT00498043 and #NCT00841945. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/28251914; hal-01547802; https://hal.science/hal-01547802Test; https://hal.science/hal-01547802/documentTest; https://hal.science/hal-01547802/file/Rituximab%20Exposure%20is%20Influenced_accepted.pdfTest; PUBMED: 28251914 |
| DOI: | 10.1182/blood-2016-10-744292 |
| الإتاحة: | https://doi.org/10.1182/blood-2016-10-744292Test https://hal.science/hal-01547802Test https://hal.science/hal-01547802/documentTest https://hal.science/hal-01547802/file/Rituximab%20Exposure%20is%20Influenced_accepted.pdfTest |
| حقوق: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.71190BF3 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1182/blood-2016-10-744292 |
|---|